MPN news to expect at ASH 2023
MPNRF | November 29, 2023
Each year at the Annual Meeting of The American Society of Hematology (ASH), there are more MPN research and clinical trial reports. This year, some unique highlights include 16 topics we find notable, along with many others with a potential connection to MPNs.
- Artificial intelligence (AI) to differentiate between essential thrombocythemia and prefibrotic primary myelofibrosis.
- New evidence and treatments to personalize MPN care for better outcomes.
- Advances in alleviating or reducing anemia.
- Sequencing and optimizing new drugs and combination drug therapies.
- Tools to enhance diversity, equity and inclusion in hematology clinical trials.
- Natural killer cells – a new frontier for immunotherapy.
- Defining low-risk vs high-risk MPNs without reliance on bone marrow biopsies.
- Reducing phlebotomy and enlarged spleen with safer dosing of idasanutlin.
- Firstline treatment of polycythemia vera with ruxolitinib.
- Treating MF JAK inhibitor naïve patients with pelabresib and ruxolitinib
- Impact of cytoreductive drugs on adolescents and young adults with ET and PV.
- Interferon-A vs hydroxyurea for untreated MPNs or patients unable to take ruxolitinib.
- Altering disease trajectory, enhancing survival with naviticlax and ruxolitinib.
- Management of bleeding risks for MPN patients undergoing unrelated surgeries.
- Understanding CALR mutations have lower risk of clots (thrombosis), higher risk of ET progression.
- Early preclinical research i.e., identification of agent that targets JAK2V617F mutation with potential to eliminate mutant cells, induce molecular remission.
MPNRF Supported Researchers Represented at ASH 2023
- TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms. Ann Mullally, MD, PhD, Dana-Farber Cancer Institute, et al. Dr. Mullally is a member of the MPNRF Scientific Advisory Board and collaborator on a 2022 MPN Thrive Initiative project.
- Clinical Factors but Not Somatic Mutations Predict for Survival in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Cell Transplant: Analysis of the North American Myelofibrosis Transplant Outcome (NAMTO) Study. Roni Tamari, MD, Memorial Sloan Kettering, et al. Emerging Opportunity Award.
- Single Cell Transcriptomics Reveal That HMGA1 Chromatin Regulators Drive Transcriptional Networks Involved in Megakaryocyte Expansion, Platelet Activation, and Interferon Signaling in JAK2V617F Myeloproliferative Neoplasms Linda Resar, MD, Johns Hopkins, et al. 2020 MPNRF Progression Research Network award.
- Targeting the JAK2V617F Hematopoietic Stem Cell through Beta1 Integrin (confex.com). Shinobu Matsuura , PhD, DVM, University School of Medicine, et al. MPNRF Thrive 2022 award recipient.
- Chromothripsis Orchestrates Leukemic Transformation in Blast Phase MPN through Targetable Amplification of DYRK1A (confex.com) John Crispino, PhD, St. Jude Childrens Research Hospital, et al. MPNRF Thrive 2022 award recipient.
.